Jaime P. Almandoz

3 weeks ago | ajmc.com | Maggie L. Shaw |Jaime P. Almandoz

In this second half of a recent interview on trends in tirzepatide use, Jaime Almandoz, MD, MBA, calls for scalable, team-based care models to support the growing use of obesity medications like tirzepatide. Integrating pharmacotherapy with nutrition, behavioral health, and surgery is essential—but so is equitable, sustained access. Almandoz stresses the need for better training in access navigation.

2 months ago | ajmc.com | Maggie L. Shaw |Jaime P. Almandoz

Tirzepatide was first approved for use in the US in May 2022, when it received an indication for adult patients with type 2 diabetes.1 Indications for chronic weight management and sleep apnea quickly followed over the next 2-plus years.2,3 The dual glucagon-like peptide-1 receptor agonist and glucose-dependent insulinotropic polypeptide receptor agonist has been praised for its safety and efficacy,4,5 while also being called out for its cost.6,7 A recent article published in Annals of...

Aug 29, 2024 | newswise.com | Jaime P. Almandoz

Since anti-obesity medications such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have become more widely known and prescribed, they have been touted as game-changing treatments for chronic overweight and obesity. Anti-obesity medications work by signaling the brain that we have eaten and the stomach is full, so patients feel satisfied with less food for longer, and cravings are diminished.

May 5, 2024 | onlinelibrary.wiley.com | Daniel Galvan |Jaime P. Almandoz |Paola Lockhart Pastor |Ofelia Negrete Vasquez

1 INTRODUCTION There is compelling evidence that excess adiposity is a risk factor for chronic kidney disease (CKD) and progression to end-stage kidney disease (ESKD).1 Obesity is estimated to be a contributing factor in 20%–25% of kidney disease cases worldwide.2 Obesity-related kidney injury is multifactorial.